Type II combi-molecules: Design and binary targeting properties of the novel triazolinium-containing molecules JDD36 and JDE05

Anti-Cancer Drugs

Volumn 18, Issue 2, 2007, Pages 171-177

  Qiu, Qiyu ^a   Domarkas, Juozas ^a   Banerjee, Ranjita ^a   Katsoulas, Athanasia ^a   McNamee, James P ^b   Jean Claude, Bertrand J ^a  

^a ROYAL VICTORIA HOSPITAL   (Canada)

^b HEALTH CANADA   (Canada)

Author keywords

Anti cancer; BCTIC; Bis targeting; DNA damage; Epidermal growth factor receptor inhibition

Indexed keywords

5 [3,3 BIS(2 CHLOROETHYL) 1 TRIAZENE]IMIDAZOLE CARBOXAMIDE; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; JDD 36; JDE 05; QUINAZOLINE DERIVATIVE; SULFORHODAMINE B;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL ASSAY; CELL PROLIFERATION; CELL STRAIN LNCAP; CELL SURVIVAL; COMET ASSAY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA DAMAGE; DRUG DESIGN; DRUG INHIBITION; DRUG MECHANISM; DRUG POTENCY; DRUG SELECTIVITY; DRUG TARGETING; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE TARGETING; HUMAN; HUMAN CELL; IC 50; MICROELECTROPHORESIS; MITOGENESIS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN ISOLATION; PROTEIN PHOSPHORYLATION; RECEPTOR BLOCKING; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL DIVISION; COMET ASSAY; DNA DAMAGE; DRUG DELIVERY SYSTEMS; DRUG DESIGN; ENZYME-LINKED IMMUNOSORBENT ASSAY; FIBROBLASTS; GENES, ERBB-1; GENES, ERBB-2; HUMANS; MALE; MICE; NIH 3T3 CELLS; PHOSPHORYLATION; PROSTATIC NEOPLASMS;

EID: 33845688396     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e3280115fe8     Document Type: Article

References (26)

1. Tanner B, Kreutz W, Meinert R, Knapstein PG, Becker R. Prognostic significance of c-erbB2 mRNA in ovarian carcinoma. Gynecol Oncol 1996; 62:268-277.
2. Morris MJ, Scher HI. Novel strategies and therapeutics for the treatment of prostate carcinoma. Cancer 2000; 89:1329-1348.
3. Grasso AW, Wen D, Miller CM, Rhim JS, Pretlow TG, Kung HJ. ErbB kinases and NDF signaling in human prostate cancer. Oncogene 1997; 15:2705-2716.
4. Yacoub A, McKinstry R, Hinman D, Chung T, Dent P, Hagan MP. Epidermal growth factor and ionizing radiation up-regulate the DNA repair genes XRCC1 and ERCC1 in DU145 and LNCaP prostate carcinoma through MAPK signaling. Radiat Res 2003; 159:439-452.
5. Hagan M, Yacoub A, Dent P. Ionizing radiation causes a dose-dependent release of transforming growth factor alpha in vitro from irradiated xenografts and during palliative treatment of hormone-refractory prostate carcinoma. Clin Cancer Res 2004; 10:5724-5731.
6. Matheson S, McNamee J, Jean-Claude BJ. Design of a chimeric 3-methyl-1,2,3-triazene with mixed receptor tyrosine kinase and DNA damaging properties: a novel tumour targeting strategy. J Pharmcol Exp Ther 2001; 296:832-840.
7. Matheson SL, McNamee JP, Wang T, Aloui-Jamali MA, Tari A, Jean-Claude BJ. The Combi-Targeting concept: dissection of the binary mechanism of action of the combi-triazene SMA41 in vitro and antiproliferative effects in vivo. J Pharmacol Exp Ther 2004; 311:1163-1170.
8. Banerjee R, Rachid Z, McNamee J, Jean-Claude BJ. Synthesis of a prodrug designed to release multiple inhibitors of the epidermal growth factor receptror (EGFR) tyrosine kinase and an alkylating agent: a novel tumour targeting concept. J Med Chem 2003; 46:5546-5551.
9. Qiu Q, Dudouit F, Banerjee R, McNamee JP, Jean-Claude BJ. Inhibition of cell signaling by the combi-nitrosourea FD137 in the androgen independent DU145 prostate cancer cell line. Prostate 2004; 59:13-21.
10. Rachid Z, Brahimi F, Katsoulas A, Teoh N, Jean-Claude BJ. The combitargeting concept: chemical dissection of the dual targeting properties of a series of 'combi-triazenes'. J Med Chem 2003; 46:4313-4321.
11. Shealy YF, Krauth CA, Holum LB, Fitzgibbon WE. Synthesis and properties of the anti-leukemic agent 5(or4)-[3,3-Bis(2-chloroethyl)-1-triazeno]imidazole- 4(or5)-carboxamide. J Pharm Sci 1968; 57:83-86.
12. Shealy YF, O'Dell CA, Krauth CA. 5-[3-2-(Chloroethyl)-1-triazeny] inidazole-4-carboxamide and a possible mechanism of action of 5-[3,3-Bis(2-chloroethyl)-1-triazeny]imidazole-4-carboxamide. J Pharm Sci 1975; 64:177-179.
13. Rewcastle GW, Denny WA, Bridges AJ, Hairong Z, Cody DR, McMichael A, Fry DW. Tyrosine kinase inhibitor. Synthesis and structure-activity relationships for 4-(phenylamino)-and 4-(phenyamino)quinazolines as potent adenosine 5′-triphosphate finding site inhibitors of the tyrosine kinase domain of the epidermal growth factor receptor. J Med Chem 1995; 38:3482-3487.
14. 6-alkylguanine-DNA alkyltransferase. Prog Nucleic Acid Res Mol Biol 1995; 51:167-223.
15. - phenotypes by a series of alkyltriazenylimidazoles. Carcinogenesis 1986; 2:259-265.
16. + and MER- human tumor cells. Cancer Res 1990; 50:7908-7911.
17. Tisdale MJ. Antitumor imidazotetrazeines XV. Role of guanine O-6-alkylation in the mechanism of cytotoxicity of imidazotetrazinones. Biochem Pharmacol 1986; 36:457-462
18. Nakamura Y, Oka M, Soda H, Shiozawa K, Yoshikawa M, Itoh A, et al. Gefitinib ('Iressa', ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance. Cancer Res 2005; 65:1541-1546.
19. Von Pawel J. Gefitinib (Iressa, ZD1839): a novel targeted approach for the treatment of solid tumors. Bull Cancer 2004; 91:E70-E76.
20. Hobday TJ, Perez EA. Molecularly targeted therapies for breast cancer. Cancer Control 2005; 12:73-81.
21. Bussolati G, Montemurro F, Righi L, Donadio M, Aglietta M, Sapino A. A modified trastuzumab antibody for the immunohistochemical detection of HER-2 overexpression in breast cancer. Br J Cancer 2005; 92:1261-1267.
22. Ciardiello F, Bianco R, Damiano V, De Lorenzo S, Pepe S, De Placido S, et al. Antitumor activity of sequential treatment with topotecan and antiepidermal growth factor receptor monoclonal antibody C225. Clin Cancer Res 1999; 5:909-916.
23. McNamee JP, Mclean JR, Ferrarotto CL, Bellier PV. Comet assay: rapid processing of multiple samples. Mutat Res 2000; 466:63-69.
24. Ciardiello F, Caputo R, Bianco R, Damianco V, Pomatico G, De Placido S, et al. Antitumour effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-sensitive tyrosine kinase inhibitor. Clin Cancer Res 2001; 6:2053-2063.
25. Dancey JE, Freidlin B. Targeting epidermal growth factor receptor: are we missing the mark? Lancet 2003; 362:62-64.
26. Magné N, Fischel JL, Dubreuil A, Formento P, Marcié S, Lagrange JL, et al. Sequence-dependent effects of ZD 1839 ('Iressa') in combination with cytotoxic treatment in human head and neck cancer. Br J Cancer 2002; 86:819-827.